Contents

List of Contributors XVII
Foreword XXI

1 Introduction to the Book 1
Alexander Schuhmacher, Oliver Gassmann, and Markus Hinder
Reference 8

2 Global Epidemiological Developments 11
Stephan Luther and Peter Schmitz
2.1 Introduction 11
2.2 Model of Epidemiological Transition 12
2.3 Global Burden of Diseases 15
2.3.1 Trends in the Distribution of Disease Burden 16
2.4 Infectious Diseases 20
2.4.1 (Re-)emerging Infectious Diseases 23
2.4.2 Neglected Tropical Diseases 26
2.5 Noncommunicable Diseases 29
2.6 Antimicrobial Resistance 32
2.7 Dynamics 35
References 38

3 The Value of Pharmaceutical Innovation: Concepts and Assessment 45
Sam Salek and Paul Kamudoni
3.1 Introduction 45
3.2 Concepts and Definitions of Value 46
3.3 Stakeholder’s Perspectives on Value 47
3.3.1 Drug Regulatory Agencies 47
3.3.2 Health Technology Assessment 47
3.3.3 Patients 49
3.3.4 Prescribers/Clinicians 49
3.4 Recent Developments Influencing the Definition and Assessment of Value 50
3.5 Recommendations: Implications for R&D  51
3.6 Discussion  52
3.7 Conclusion  56
References  57

4  A Review of the Pharmaceutical R&D Efficiency: Costs, Timelines, and Probabilities  61
Alexander Schuhmacher, Oliver Gassmann, and Markus Hinder
4.1 Introduction  61
4.2 The Historical Perspective  62
4.3 The R&D Phase Model  63
4.4 The Low R&D Success Rates  63
4.5 The Long R&D Time Intervals  67
4.6 The High Cost of Pharmaceutical R&D  71
4.7 The Reduced R&D Efficiency  73
4.8 Can an Increase in R&D Value Compensate the Reduced R&D Efficiency?  76
References  78

5  Financing Pharmaceutical Innovation  81
Sviataslau Sivagrakau
5.1 Introduction  81
5.2 Measuring Innovation: Categories of New Drugs  84
5.3 Productivity of Pharmaceutical Industry throughout Time  86
5.4 Measuring the Cost of Developing New Medicines  87
5.5 Funding Drug Development: a Global Endeavor  91
5.6 Public and Private Funds: Complementary Finance for Drug Development  95
5.7 How Commercial Drug Development Projects Are Financed Today: Big Firms, Small Firms, and Their Cooperation  97
5.8 Public Health Economics and Financing Pharmaceutical Innovation  99
5.9 Conclusion  101
Acknowledgment  102
References  102

6  Challenges and Options for Drug Discovery  107
Werner Kramer
6.1 Introduction  107
6.2 Paradigm Shifts of R&D Organizations  108
6.3 Productivity of Drug Discovery  109
6.4 Is There an Innovation Gap in Biomedical Research?  111
6.4.1 To Go for First in Class or Best in Class  112
6.4.2 How We Define Medical Innovation?  112
6.5 Why Did Drug Candidates Fail? 113
6.5.1 Why Is the Dropout Rate So High in Early Clinical Development? 115
6.5.1.1 Drug Behavior In Vivo: Role of Transport Proteins 115
6.5.1.2 Hypes and Lack of Scientific Thoroughness 116
6.6 Implications from the "Lessons Learnt" for Future Drug Discovery Research 123
6.6.1 Organization of Drug Discovery and Development 123
6.6.2 Elucidation of the Physiological Validity of a Target for the Human Disease 125
6.6.2.1 Extensive Inquiry of (All) Published Data of a Target or Pathway 125
6.6.2.2 Integrative Knowledge Management 127
6.6.2.3 Demonstration of the Involvement of a Target in Human Disease 128
6.6.2.4 A Stringent and Comprehensive Test Sequence 132
6.6.2.5 Translational Clinical Trials 135
Acknowledgment 136
References 136

7 Translational Medicine: Enabling the Proof of Concepts 141
Gezim Lahu and John Darbyshire
7.1 Introduction 141
7.2 Translational Medicine and Its Role/Value in Early Development 143
7.3 Knowledge Generation 144
7.4 Types of Data, Experiments, and Tools Needed to Move from Basic Research to Early Clinical Development 144
7.4.1 Dose Selection 145
7.4.2 Animal Models 146
7.4.3 Fraction of NOAEL and Efficacious Dose 149
7.4.4 Allometric Scaling and PBPK 150
7.4.5 Physiologically Based Pharmacokinetic Models PBPK 151
7.4.6 Pharmacokinetic and Pharmacodynamic Modeling 151
7.5 FIM (Dose Escalation and MTD) 153
7.6 Proof of Concept (PoC) 154
Summary 156
References 157

8 Preclinical Safety and Risk Assessment 161
Paul Germann and Rob Caldwell
8.1 Introduction 161
8.2 Test Systems 161
8.2.1 In Silico Analysis 161
8.2.2 In Vitro Experiments 162
8.3  Case Study: hERG Assay  163
8.3.1  In Vivo Experiments  164
8.4  The Preclinical "Package" during the Development of an NME  165
8.5  Factors Influencing the Preclinical Data Set  166
8.5.1  Timing and Costs  167
8.5.2  Intended Clinical Application Route  167
8.5.3  Treatment Duration and Treatment Frequency  167
8.5.4  Clinical Indication  167
8.5.5  Ongoing Changes of the Regulatory Landscape  168
8.5.6  New Drug Formats  168
8.6  Translation into Humans: The "Therapeutic Window"  169
8.7  Influence of Intended Therapeutic Use on the Risk Assessment (RA)  169
8.8  Deep Dive Case Study: Safety Assessment of Biological Drug Formats  170
8.9  NBE Case Study 1  175
8.10  NBE Case Study 2  175
8.11  Carcinogenicity Risk Assessment for Marketed Drugs  176
8.12  Treatment Duration  178
8.13  Conclusion – the "Art" of Preclinical Safety: Summarizing the Concept of Hazard Identification and Description, Risk Assessment, and Risk Management  179
Acknowledgment  179
Disclosures  180
References  180

9  Developing Commercial Solutions for Therapeutic Proteins  183
Galina Hesse
9.1  Introduction  183
9.2  Developing Commercial Solutions for Therapeutic Proteins  184
9.2.1  Defining a Target Product Profile  184
9.2.2  Developing Formulations for Therapeutic Proteins  186
9.2.3  Testing Formulations for Therapeutic Proteins  188
9.2.4  Development of Primary Containers  188
9.2.5  Development of Application Systems  190
9.3  Quality by Design  192
9.4  Examples for Innovations in Manufacture of Sterile Pharmaceutical Products  194
9.5  Summary  197
List of FDA/ICH Guidances Referenced  198
Disclaimer  199
References  199
10 The Evolution of Clinical Development: From Technical Success to Clinical Value Creation  203
Markus Hinder and Alexander Schuhmacher

10.1 Introduction  203
10.2 CD: Changes and Challenges  204
10.2.1 Clinical Endpoints: From Symptom-Oriented Endpoints to Hard and Predefined Endpoints  204
10.2.2 Determination and Quantification of Risks  205
10.2.3 Assessment of Medical Progress in Context of Available Therapeutic Options  206
10.2.3.1 EbM  206
10.2.3.2 Health Economics, Pharmacoeconomics, and the Fourth Hurdle  207
10.2.3.3 Results of These Changes and Challenges  208
10.3 Technical Success and Clinical Value Creation in CD in the Future  208
10.3.1 Established and Novel Approaches to Determine the Dose–Exposure–Response Relationship  210
10.3.2 Comparators  212
10.3.3 Patient Stratification to Increase Treatment Response and Benefit and Reduce Risk  212
10.3.4 New Operational Tools to Succeed in Trials with Increased Complexity, Special Populations, or Large Size  213
10.3.5 Collaboration and Outsourcing as Tools to Work in Networks  214
10.3.6 Collaboration across Sectors and Industries to Boost the Next Wave of Innovation  215
Disclaimer  218
References  218

11 Translational Development  225
Nigel McCracken

11.1 Introduction  225
11.1.1 Legacy  226
11.2 Translational Development  227
11.2.1 TP  228
11.2.2 Translational Toolkit  229
11.3 Dose Optimization  230
11.3.1 Physicochemical Properties  231
11.3.2 Target Affinity and Selectivity  231
11.3.3 Clearance  231
11.3.4 Prediction of Human Dose  232
11.4 Pharmacogenomics  233
11.4.1 Patient Segmentation  233
11.4.2 Disease Segmentation  234
11.4.3 Utility  237
11.5 Biomarker Development 238
11.5.1 Biomarker Activities 239
11.5.2 Assessing the Opportunity 239
11.6 Systems Pharmacology 240
11.7 Rational Drug Development 241
11.8 Concluding Remarks 242
References 242

12 Forty Years of Innovation in Biopharmaceuticals – Will the Next 40 Years Be as Revolutionary? 245
Mathias Schmidt, Sanjay Patel, Petter Veiby, Qiang Liu, and Michael Buckley
12.1 Introduction 245
12.1.1 The Value Proposition of Biologics 246
12.1.1.1 The Patient Perspective 246
12.1.1.2 The Pharmaceutical Industry’s Perspective 248
12.1.2 Biosimilars: A Blessing or a Threat to Innovation? 250
12.1.3 Further Innovation in Biologics – Incremental or Revolutionary? 252
12.2 The Evolution of Biologics Manufacturing 252
12.2.1 Introduction 252
12.2.2 CHO Cells: The Industry Workhorse 253
12.2.3 Protein Production Strategies 253
12.2.4 The Impact of Increasing Titers on Manufacturing Facilities 255
12.2.5 Protein Purification Platforms 256
12.2.6 Conclusion: What Will the Next 40 Years of Innovation Bring? 258
12.3 The Evolution of Alternative Scaffolds 259
12.3.1 Novel Small Protein Scaffolds 260
12.3.2 Single-Chain Fragment Variables and Diabodies 260
12.3.3 Single-Domain Antibodies 261
12.3.4 Nonantibody Scaffolds 261
12.3.5 Bispecific Single-Chain Fragment Variables and Diabodies 263
12.3.6 Other Bispecific Antibody Formats 264
12.4 Antibody-Drug Conjugates 265
12.5 The Next Wave of Biologics 270
12.5.1 Orally Available Biologics 271
12.5.2 Biologics That Enter the Cytoplasm 271
12.5.3 Biologics That Pass the Blood–Brain Barrier 272
12.5.4 Translational Medicine as Driver of Innovation 272
Disclaimer 273
References 273

13 Vaccines: Where Inertia, Innovation, and Revolution Create Value, Simultaneously and Quietly 277
Pierre A. Morgon and Hannah Nawi
13.1 Introduction 277
14.9 The Role of the Key Stakeholders in Shaping a New Regulatory Framework 323
14.10 The Consequences for the Healthcare Industry in Terms of Governance and Capabilities 325
14.11 The Sustainable Path Forward for the Healthcare Industry 329
14.11.1 Take-Home Messages 331
References 332

15 The Pharmaceutical Industry is Opening Its R&D Boundaries 335
Alexander Schuhmacher and Ulrich A. K. Betz
15.1 Introduction 335
15.2 Open Innovation versus Closed Innovation 336
15.3 Business Models in an Open Innovation Framework 341
15.4 Open Innovation Processes 342
15.5 Capabilities and Attitudes Enabling Open Innovation 344
15.6 Open Innovation in the Pharmaceutical Industry 345
15.6.1 The More Traditional Elements of Open Innovation 345
15.6.1.1 Target Scouting 345
15.6.1.2 Research Collaborations 346
15.6.1.3 Drug Licensing 346
15.6.1.4 Outsourcing 348
15.6.1.5 Joint Ventures 349
15.6.2 The Newer Concepts of Open Innovation 349
15.6.2.1 New Frontier Science 350
15.6.2.2 Drug Discovery Alliances 350
15.6.2.3 Private–Public Partnerships 351
15.6.2.4 Innovation Incubator 351
15.6.2.5 Virtual R&D 352
15.6.2.6 Crowdsourcing 353
15.6.2.7 Open Source Innovation 355
15.6.2.8 Innovation Camps 355
15.6.2.9 Fluctuating Open Teams 356
15.7 New Business Models in View of the Potential of Open Innovation 356
15.7.1 General Trends in the Pharmaceutical Industry 356
15.8 Outlook 358
References 359

16 Out-Licensing in Pharmaceutical Research and Development 363
Oliver Gassmann, Carol A. Krech, Martin A. Bader, and Gerrit Reepmeyer
16.1 Introduction 363
16.2 Performance-Based R&D Collaborations on the Rise 364
16.3 The Impact of Collaborations on the Value Chain 365
16.4 Generating Value from Pipeline Assets by Out-Licensing 367
16.5 Pharmaceutical Companies’ Resistance toward Out-Licensing 372
16.6 Managing Out-Licensing at Novartis: A Case Study 372
  16.6.1 Out-Licensing as a 10-Step Process 373
  16.6.2 Out-Licensing Contract Design 375
  16.6.3 Structure of the Out-Licensing Collaboration with Speedel 375
16.7 Future Directions and Trends 377
References 378

17 Trends and Innovations in Pharmaceutical R&D Outsourcing 383
  Antal K. Hajos
  17.1 Introduction 383
  17.2 Drivers to the Use of Outsourcing 383
    17.2.1 Overview on the CRO Market 383
    17.2.2 Core versus Noncore Activities 387
  17.3 Genesis of Outsourcing in the Twentieth Century: From Commodity to Contribution 388
    17.3.1 Outsourcing Portfolio and the Move to Full-Service Provision 388
    17.3.2 Globalization and the Emerging Market Hype 389
    17.3.3 Procurement Takes over the Outsourcing Function 391
  17.4 Current and Future Trends in Outsourcing: From Contribution to Innovation 392
    17.4.1 How Has Outsourcing Itself Innovated and What Are the Future Trends? 392
    17.4.2 How Does and Will Outsourcing Contribute to Innovation? 394
  17.5 Discussion and Conclusion 395
References 398

18 New Innovation Models in Pharmaceutical R&D 401
  Alexander Schuhmacher, Oliver Gassmann, and Markus Hinder
  18.1 Introduction 401
  18.2 Some Attempts That Were Recommended in the Past 402
  18.3 The Increasing Pipeline Size 403
  18.4 The Reduction of R&D Investments 404
  18.5 The Opening of the R&D Processes 407
  18.6 The Challenge with the Return on Investment 411
  18.7 Changing the R&D Processes Is Not Enough 412
  18.8 What Is the Best R&D Model? 413
References 414

19 The Influence of Leadership Paradigms and Styles on Pharmaceutical Innovation 416
  Aubyn Howard
  19.1 Introduction 417
  19.2 What Is Your Concept or Model of Good Leadership? 419
  19.3 Approaches to Leadership Modeling and Profiling 420
    19.3.1 Personality Types 421
19.3.2 Behavioral Preferences 421
19.3.3 Developmental Stages 421
19.3.4 Competency Frameworks 421
19.4 The Developmental Approach to Leadership Paradigms and Styles 422
19.5 Inner and Outer Leadership 424
19.6 Dynamics of How Leadership Paradigms Evolve 425
19.6.1 Magic – Animistic 426
19.6.2 Impulsive – Egocentric 427
19.6.3 Conformist – Absolutist 428
19.6.4 Achievement – Multiplistic 429
19.6.5 Pluralistic – Relativistic 430
19.6.6 Evolutionary – Systemic 432
19.7 Leadership at Different Levels within Pharma 433
19.8 Optimizing Innovation in Different Organizational Models and Cultures 437
19.9 How Do We Support the Development of Evolutionary Leaders? 439
19.10 What Does It Mean to Operate from the Evolutionary Paradigm? 440
19.11 Leadership and Personal Mastery 441
19.12 Building an Evolutionary Bridge to Release Innovation 442
19.13 Conclusions 445

References 446

20 The Role of Modern Portfolio Management in Pharma Innovation 449
Joachim M. Greuel and Axel Wiest
20.1 Introduction 449
20.2 Challenges in R&D and the Origin of Pharmaceutical Portfolio Management 450
20.3 Goals and Metrics of Portfolio Management 451
20.4 Portfolio Management as Enabler of Innovation 456
20.5 Modern Portfolio Management Integrates In-House R&D, Business Development, and M&A 457
References 458

21 Patent Management Throughout the Innovation Life Cycle 461
Martin A. Bader and Oliver Gassmann
21.1 Introduction 461
21.2 The Changing Role of Patents: From Legal to Strategic 462
21.3 The Patent Life Cycle Management Model 467
21.3.1 Exploration 468
21.3.2 Generation 469
21.3.3 Protection 469
21.3.4  Optimization  470
21.3.5  Decline  470
21.4  Example: Managing IP Rights at Bayer  471
21.5  Concluding Remarks  472
References  473

Index  475